Ogilvy Ouster in Doubt

Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.

WASHINGTON — Now that Ogilvy & Mather’s main adversary in the House of Representatives has lost his re-election bid, the shop’s odds of surviving lawmakers’ efforts to bar it from the White House anti-drug media campaign will improve if the Senate defers action on an appropriations bill until next year.

The Senate could adopt a “continuing resolution,” as the House did last week, which would maintain the White House Office of National Drug Control Policy campaign at the current level of $180 million and retain Ogilvy until the January session.

AW+

WORK SMARTER - LEARN, GROW AND BE INSPIRED.

Subscribe today!

To Read the Full Story Become an Adweek+ Subscriber

View Subscription Options

Already a member? Sign in